CROWN CORONATION: COVID-19 Research Outcomes Worldwide Network for CORONAvirus prevenTION

COVID 19 Clinical Trial

— CROWN CORONA  

Official title:

An International, Multi-site, Bayesian Platform Adaptive, Randomized, Placebo-controlled Trial Assessing the Effectiveness of Candidate Agents in Mitigating COVID-19 Disease in Adults

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04333732
• Other study ID #: 202004099
• Secondary ID: INV-017499
• Status: Completed
• Phase: Phase 3
• Start date: September 4, 2020
• Est. completion date: December 3, 2021

Study information

• Verified date: January 2024
• Source: Washington University School of Medicine
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objective of CROWN CORONATION is the prevention of symptomatic COVID-19 by using combinations of approved and safe repurposed interventions, with complementary mechanisms of action.

Description:

CROWN CORONATION is an international, Bayesian platform adaptive, randomized, placebo-controlled trial assessing the effectiveness of candidate interventions in preventing COVID-19 disease in adults. Randomization will be stratified by age (<50 and ≥50) and site. Participants will be healthcare workers at risk of contracting SARS-CoV-2. Participants will be randomized into one of two arms: - Education and surveillance plus MR or MMR vaccine - Education and surveillance plus Placebo While the initial intervention to be tested on the platform will be the MR or MMR vaccine, other interventions might be added or removed over the course of the trial. The trial will evaluate which of the intervention arms is most effective at decreasing the incidence of symptomatic COVID-19 disease, without unacceptable side effects or safety events. All participants will require be required to have a mobile phone to participate. This is standard in all the countries in this study. Most, but not all, will also have a smartphone. Participants will complete weekly data logs via SMS texting. Follow-up information will be collected until approximately 5 months after the end of treatment or death. Participants who develop symptomatic COVID-19 during the last month of observation will at a minimum be followed-up until symptom resolution and at a maximum until 6 months after randomization (whichever comes first). Telemedicine approaches to collecting information on participants will be used where possible. The trial will provide adherence support interventions that have been shown in randomized controlled trials to improve adherence to Human Immunodeficiency Virus treatment and adapted for HIV Pre-Exposure Prophylaxis (HIV PrEP) (e.g. two-way SMS with check in for those that report symptoms or adverse events). The database will be hosted on UK-based servers which are expected to be managed by Sealed Envelope Ltd. Local investigators will have access to the part of the CRF to enable recording of outcome data and/or severity of COVID-19 symptoms. Participants will be given a secure login to enable them to complete an initial participant health questionnaire and the regular data logs. It is envisaged that these will be completed at least weekly.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 3411
• Est. completion date: December 3, 2021
• Est. primary completion date: August 10, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion criteria

1. Volunteers without clinical evidence of COVID-19 infection aged 18 years and older.

2. Healthcare workers based in a primary, secondary or tertiary healthcare setting with a high risk of developing COVID-19 due to their potential exposure to patients with SARS-CoV-2 infection.

3. Must have a mobile phone and access to the Internet for data collection purposes.

4. Participants who are willing and able to provide informed consent via an electronic consent process. Exclusion criteria

1. Prior enrollment into other COVID-19 interventional prevention or treatment trials (observational trials not excluded).

2. Self-reported or diagnosed current infection with SARS-CoV-2 or previous COVID-19 diagnosis.

3. Self-reported current acute respiratory infection.

4. Concurrent and/or recent involvement in other research or use of the investigational product, a product considered to be equivalent to the investigational product, or any other product that is likely to interfere with the investigational products in this trial used within three months of study enrolment.

5. Self-reported known allergies to any of the IMPs and excipients of the IMPs and placebo.

6. Self-reported presence or history of the conditions listed in the appendices.

7. Self-reported current use of medication known to interact with any of the medications listed in the appendices.

8. Inability or unwillingness to be followed up for the trial period. For M-M-R II

• Pregnant women.
• Individuals receiving high dose corticosteroids, other immuno-suppressive drugs, alkylating agents or anti-metabolites.
• Individuals undergoing radiotherapy.
• Any malignant disease either untreated or currently undergoing therapy.
• History of administration of gammaglobulin or blood transfusions within the previous 3 months.
• Participants with an allergy to the MR (MMR) vaccine or its components, including neomycin.
• Idiopathic thrombocytopenic purpura (ITP)
• Untreated tuberculosis
• Prior receipt of any vaccines (licensed or investigational) =30 days before enrollment
• Planned receipt of any vaccine other than the study intervention within 30 days before and after the study vaccination (not including the flu vaccination via injection)
• Prior receipt of an investigational or licensed vaccine likely to impact on interpretation of the trial data (e.g. Adenovirus vectored vaccines, any coronavirus vaccines).
• Any confirmed or suspected immunosuppressive or immunodeficient state, including untreated HIV infection with a CD4T count <200 /mL
• Asplenia

Related Conditions & MeSH terms

• COVID 19
• COVID-19

Intervention

Drug:
• MR or M-M-R II ® vaccine
Education and surveillance plus MR or M-M-R II ® vaccine
• Placebo
Placebo injection

Locations

Country	Name	City	State
Ghana	University of Ghana Medical Centre	Accra	Greater Accra Region
South Africa	Clinical HIV Research Unit (CHRU)	Auckland Park	Johannesburg
South Africa	JOSHA Research	Bloemfontein	Free State
South Africa	FAMCRU (Family Clinical Research with Ubuntu)	Cape Town
South Africa	Groote Schuur Hospital	Cape Town	Western Cape
South Africa	Chatsworth, HIV Prevention Research Unit, South African Medical Research Council	Chatsworth
South Africa	Perinatal HIV Research Unit (PHRU)	Diepkloof	Johannesburg
South Africa	Isipingo, HIV Prevention Research Unit, South African Medical Research Council	Durban
South Africa	Wits RHI, University of the Witwatersrand	Hillbrow	Johannesburg,Gauteng
South Africa	Groote Schuur/J52, Desmond Tutu Health Foundation	Mowbray	Cape Town
South Africa	Setshaba Research Centre	Soshanguve	Tshwane
South Africa	Masiphumelele, Desmond Tutu Health Foundation	Sunnydale	Cape Town
South Africa	Aurum Institute Tembisa	Tembisa
United Kingdom	University College London	London
United States	Washington University School of Medicine	Saint Louis	Missouri
Zambia	Centre for Infectious Disease Research in Zambia [CIDRZ]	Lusaka
Zambia	Levy Mwanawasa University Teaching Hospital	Lusaka

Sponsors (2)

Lead Sponsor	Collaborator
Washington University School of Medicine	COVID -19 Therapeutics Accelerator

Countries where clinical trial is conducted

United States,  Zambia,  Ghana,  South Africa,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With Symptomatic COVID-19 at 60 Days	Incidence of symptomatic (i.e. any of the following: cough, shortness of breath or difficulty breathing, fever, chills, muscle pain, sore throat, new loss of taste or smell, nausea, vomiting, or diarrhea), laboratory test-confirmed COVID-19 in the intervention and control groups in adults with repeated exposures to SARS-CoV-2 by day 60 after receiving trial intervention.	60 days after receiving trial intervention
Secondary	Number of Participants With Symptomatic COVID-19 at 150 Days	Incidence of symptomatic (i.e. any of the following: cough, shortness of breath or difficulty breathing, fever, chills, muscle pain, sore throat, new loss of taste or smell, nausea, vomiting, or diarrhea), laboratory test-confirmed COVID-19 in the intervention and control groups in adults with repeated exposures to SARS-CoV-2 by day 150 after receiving trial intervention.	150 days after receiving trial intervention
Secondary	Severity of COVID-19 Measured at 60 Days After Intervention	Severity of COVID-19 in adults who become infected with SARS-CoV-2 by day 60 after receiving trial intervention. Severity will be graded on a simplified version of the ordinal WHO COVID-19 severity scale ((i) uninfected, (ii) infected but ambulatory [mild disease], (iii) infected and hospitalized [moderate or severe disease] or dead). Practically, this outcome measure was treated as a binary outcome - participants were classified and counted as having severe COVID-19 if they met the definition for the primary outcome of symptomatic COVID-19 AND were hospitalized during the course of their COVID-19 illness.	60 days after receiving trial intervention
Secondary	Severity of COVID-19 at 150 Days After Intervention	Severity of COVID-19 in adults who become infected with SARS-CoV-2 by day 150 after receiving trial intervention. Severity will be graded on a simplified version of the ordinal WHO COVID-19 severity scale ((i) uninfected, (ii) infected but ambulatory [mild disease], (iii) infected and hospitalized [moderate or severe disease] or dead). Practically, this outcome measure was treated as a binary outcome - participants were classified and counted as having severe COVID-19 if they met the definition for the primary outcome of symptomatic COVID-19 AND were hospitalized during the course of their COVID-19 illness.	150 days
Secondary	Risk of SARS-CoV-2 Infection up to 150 Days After Trial Intervention	Risk of SARS-CoV-2 infection by serology (anti-nucleocapsid antibody) in the intervention and control groups in adults with repeated exposures to SARS-CoV-2 by day 150 after receiving trial intervention. Infection with SARS CoV-2 during the course of the trial was diagnosed when IgG antibodies to the viral nucleocapsid protein were present from the 150 day specimen, but not the baseline specimen.	150 days